ACA and Addiction Treatment: Implications, Policy and Practice Issues
- How science has influenced the components of the ACA
- How the addiction treatment model can and should change
- Implications of the ACA and MH/SA parity on the patient profile of treatment seeking individuals
- ACA-related service delivery and payment reforms that incentivize rapid screening and access to treatment
- What policy and practice issues (e.g. workforce, clinical services, financing) still need to be addressed in a post-ACA world
Mohini Venkatesh is the Vice President of Practice Improvement at the National Council for Behavioral Health. In this position, Ms. Venkatesh leads a variety of practice improvement and leadership programs that help mental health and addiction provider organizations develop business and clinical strategies to most efficiently serve their communities. She serves as the staff policy liaison to the National Council’s network of associations throughout the states, and conducts federal legislative analysis on health reform and other policy issues. Prior to being in Washington, D.C., she worked on an inpatient psychiatric unit in a general hospital in Massachusetts and has worked at several social service non-profit organizations, including a state association advocating for community behavioral health services. Ms. Venkatesh is the board vice-chair for a community behavioral health organization in Washington, D.C. and is a fellow with the Non-Profit Roundtable’s Future Executive Directors Program. She received a Masters in Public Health from Yale University and a B.A. in Psychology from the University of Massachusetts-Amherst.
Aaron Williams serves as the Director Training and Technical Associate for Substance Abuse for the SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) at the National Council for Behavioral Health (National Council). In this role, Mr. Williams leads the National Council/CIHS’ strategic initiatives on substance use screening and treatment, and provides direct training and technical assistance services that promote primary and behavioral healthcare integration with special attention to addiction treatment providers. Prior to joining the National Council, Mr. Williams served as the Associate Director of Research and Information for the Danya Institute, Inc., and the Central East Addiction Technology Transfer Center (Central East) where he was responsible for the management, and dissemination of all research related to Institute endeavors. Mr. Williams has more than 13 years of experience in the field of behavioral health services, with an emphasis on substance abuse treatment, workforce development, and the use of evidence-based-practices in clinical settings. Over this time, Mr. Williams has written and contributed to numerous articles and reports on: drugs of abuse, workforce development of substance abuse professionals, and implementation of evidence-based practices; and demonstrated abilities in developing research plans, training protocols, as well as evaluating program effectiveness.
Dr. Timothy Condon currently is a Visiting Research Professor at the Center on Alcoholism, Substance Abuse and Addictions at the University of New Mexico. He is involved in various projects related to intersection of public health and public safety, prescriptions drug abuse, healthcare policy reform and implementation and the integration of behavioral and physical health systems. He also serves as the Chief Science Advisor to the Center for Health and Justice at TASC-IL. Prior to joining CASAA, Dr. Condon served in the White House Office of National Drug Control Policy (ONDCP) as the Science Policy Advisor to the Director. Before coming to ONDCP, Dr. Condon was appointed as Deputy Director of the National Institute on Drug Abuse (NIDA) in 2003. Through his active outreach in advancing the science of addiction and its implementation into clinical practice, Dr. Condon continues to create needed change in how drug abuse addiction is perceived and treated in this country and internationally, erasing damaging stigma and ushering in a new health paradigm that accurately views addiction as a chronic, treatable disease.